Indoco Remedies

Who are the top shareholders of the Indoco Remedies?

The top shareholders of Indoco Remedies include Spa Holdings Pvt Ltd with 19.88%, mutual funds holding 18.52%, and individual investors owning 15.99%. Notably, Nippon Life India Trustee Ltd is the largest public shareholder with 4.8%.

The top shareholders of Indoco Remedies include a mix of promoters and institutional investors. The largest promoter is Spa Holdings Pvt Ltd, which holds 19.88% of the shares. The promoters collectively hold a significant portion of the company, with no pledged promoter holdings reported. <BR><BR>In terms of institutional investors, mutual funds hold 18.52% of the shares through 8 different schemes, while foreign institutional investors (FIIs) have a smaller stake of 1.24% across 39 entities. The highest public shareholder is Nippon Life India Trustee Ltd, which manages the Nippon India Small Cap Fund and holds 4.8%. Additionally, individual investors collectively own 15.99% of the company.

What does Indoco Remedies do?

Indoco Remedies Ltd is a Mumbai-based pharmaceutical company focused on formulations, with a market cap of Rs 2,532 Cr. As of March 2025, it reported net sales of 341 Cr and a net loss of 26 Cr.

Overview: <BR>Indoco Remedies Ltd is a Mumbai-based pharmaceutical company focused on formulations, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>History: <BR>Indoco Remedies Limited was incorporated on August 23, 1947. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 341 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -26 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 2,532 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.54% <BR>Debt-Equity: 0.96 <BR>Return on Equity: -7.31% <BR>Price to Book: 2.53<BR><BR>Contact Details: <BR>Address: Indoco House 166 C S T Road, Santacruz (East) Kalina Mumbai Maharashtra : 400098 <BR>Tel: 91-022-26541851-55 <BR>Email: jagdishs@indoco.com <BR>Website: http://www.indoco.com

What is the bonus history of the Indoco Remedies?

Indoco Remedies issued a bonus share in a 1:2 ratio on May 17, 2012, with a record date of May 19, 2012. This is the most recent bonus action recorded for the company.

Indoco Remedies has a bonus history that includes a notable issue announced on May 17, 2012. The company issued a bonus in the ratio of 1:2, meaning that for every two shares held, shareholders received one additional share. The record date for this bonus was May 19, 2012. This was the most recent bonus action recorded for the company. If you have any more questions about Indoco Remedies or need further details, feel free to ask!

Has Indoco Remedies declared dividend?

Indoco Remedies Ltd has declared a 75% dividend, amounting to ₹1.5 per share, with an ex-date of September 19, 2024. Despite the dividend, the company's stock has experienced significant price declines over various periods, resulting in negative total returns in the short term.

Indoco Remedies Ltd has declared a 75% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 1.5<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.54%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.9%, with a dividend return of 0%, resulting in a total return of -14.9%.<BR><BR>Over the past year, the price return was -12.95%, the dividend return was 0.46%, leading to a total return of -12.49%.<BR><BR>In the 2-year period, the price return was -16.99%, the dividend return was 1.13%, culminating in a total return of -15.86%.<BR><BR>For the 3-year period, the price return was -27.73%, with a dividend return of 1.43%, resulting in a total return of -26.3%.<BR><BR>In the last 4 years, the price return was -29.74%, the dividend return was 1.73%, which led to a total return of -28.01%.<BR><BR>Over the 5-year period, the price return was 22.57%, with a dividend return of 3.36%, resulting in a total return of 25.93%.<BR><BR>Overall, while Indoco Remedies has declared a dividend, the total returns over various periods indicate significant price declines, particularly in the shorter terms, suggesting challenges in the company's stock performance despite the dividend declaration.

Who are the peers of the Indoco Remedies?

Indoco Remedies' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Amrutanjan Health, Syncom Formulations, Windlas Biotech, Sigachi Industries, and Beta Drugs Ltd. Indoco Remedies has average management risk and capital structure, with a 1-year return of -10.95%, outperforming only Sigachi Industries.

Peers: The peers of Indoco Remedies are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Amrutanjan Healt, Syncom Formul., Windlas Biotech, Sigachi Indust., and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Amrutanjan Healt, while Average management risk is found at Indoco Remedies, Syncom Formul., Windlas Biotech, Sigachi Indust., and Beta Drugs Ltd. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is noted for Divi's Lab., Torrent Pharma, Indoco Remedies, Amrutanjan Healt, Syncom Formul., Windlas Biotech, Sigachi Indust., and Beta Drugs Ltd. Excellent capital structure is seen in Sun Pharma.Inds., Divi's Lab., Cipla, and Amrutanjan Healt, while average capital structure is found at Indoco Remedies, and good capital structure is noted for Torrent Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Sigachi Indust. at -17.67%. Indoco Remedies has a 1-year return of -10.95%, which is higher than Sigachi Indust. but lower than all other peers. Additionally, the six-month return is negative for Indoco Remedies, Sun Pharma.Inds., Torrent Pharma, and Windlas Biotech.

Is Indoco Remedies overvalued or undervalued?

As of May 23, 2025, Indoco Remedies is considered overvalued and risky due to troubling financial ratios, including a PE ratio of -33.83 and negative returns year-to-date, especially when compared to more profitable peers like Sun Pharma and Cipla.

As of 23 May 2025, the valuation grade for Indoco Remedies has moved from attractive to risky, indicating a significant shift in perception regarding its financial health. The company is currently assessed as overvalued, given its troubling financial ratios, including a PE ratio of -33.83, an EV to EBIT ratio of -240.53, and a ROE of -7.31%. These figures suggest that the company is struggling to generate profits and is not performing well compared to its peers.<BR><BR>In comparison to industry peers, Indoco Remedies stands out unfavorably; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights the challenges Indoco Remedies faces in the current market environment. Additionally, while the stock has recently outperformed the Sensex over the past week and month, its year-to-date and one-year returns remain negative, further reinforcing the notion that the stock is overvalued in light of its financial performance.

When is the next results date for Indoco Remedies?

Indoco Remedies will announce its results on 24 July 2025.

Indoco Remedies will declare its results on 24 July 2025.

Who are in the management team of Indoco Remedies?

As of March 2023, the management team of Indoco Remedies includes Suresh G Kare (Chairman & Wholetime Director), Aditi Kare Panandikar (Managing Director), Sundeep V Bambolkar (Joint Managing Director), and several independent and non-executive directors. They oversee the company's operations and strategic direction.

As of March 2023, the management team of Indoco Remedies includes the following individuals:<BR><BR>1. Suresh G Kare - Chairman & Wholetime Director<BR>2. Aditi Kare Panandikar - Managing Director<BR>3. Sundeep V Bambolkar - Joint Managing Director<BR>4. Rajiv Kakodkar - Independent Non-Executive Director<BR>5. D M Gavaskar - Independent Non-Executive Director<BR>6. Vasudha V Kamat - Independent Non-Executive Director<BR>7. Abhijit Y Gore - Independent Non-Executive Director<BR>8. Anand Nadkarni - Non-Executive Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

How big is Indoco Remedies?

As of 24th July, Indoco Remedies Ltd has a market capitalization of 2,907.00 Cr, with recent net sales of 1,671.31 Cr and a net profit loss of 112.14 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Indoco Remedies Ltd has a market capitalization of 2,907.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,671.31 Cr, while the sum of Net Profit for the same period shows a loss of 112.14 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds stand at 1,109.90 Cr, and Total Assets are valued at 2,144.73 Cr.

How has been the historical performance of Indoco Remedies?

Indoco Remedies has experienced fluctuating financial performance, with net sales decreasing to 1,664.92 Cr in March 2025 from 1,817.29 Cr in March 2024, and a significant drop in operating profit leading to a profit before tax of -74.37 Cr. Despite an increase in total assets, the company faces challenges in profitability, as reflected by a profit after tax of -77.95 Cr in March 2025.

Answer:<BR>The historical performance of Indoco Remedies shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Indoco Remedies reported net sales of 1,664.92 Cr in March 2025, a decrease from 1,817.29 Cr in March 2024, but an increase from 1,668.61 Cr in March 2023. The total operating income followed a similar pattern, with a total of 1,664.92 Cr in March 2025 compared to 1,817.29 Cr in the previous year. The total expenditure, excluding depreciation, was 1,565.66 Cr in March 2025, slightly down from 1,572.98 Cr in March 2024. Operating profit (PBDIT) decreased significantly to 99.26 Cr in March 2025 from 244.31 Cr in March 2024, leading to a profit before tax of -74.37 Cr in March 2025, a stark contrast to the profit of 135.80 Cr in March 2024. Consequently, profit after tax also fell to -77.95 Cr in March 2025 from 97.01 Cr in the previous year. The company's total assets increased to 2,429.91 Cr in March 2025 from 2,144.73 Cr in March 2024, while total liabilities rose to 2,429.91 Cr from 2,144.73 Cr, indicating a growing debt level. Cash flow from operating activities decreased to 94.00 Cr in March 2025 from 155.00 Cr in March 2024, and the closing cash and cash equivalents were reported at 12.00 Cr in March 2025, down from 14.00 Cr in March 2024. Overall, the financial performance of Indoco Remedies reflects challenges in profitability despite growth in sales and total assets.

Is Indoco Remedies technically bullish or bearish?

As of December 2, 2025, Indoco Remedies exhibits a neutral technical trend with mixed signals, showing a mildly bearish outlook on weekly indicators and a lack of clear direction overall.

As of 2 December 2025, the technical trend for Indoco Remedies has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are bearish, while the monthly MACD and KST are mildly bullish, indicating a lack of clear direction. The Bollinger Bands are mildly bearish on both weekly and monthly charts, reinforcing the sideways trend. Daily moving averages show a mildly bullish stance, but this is countered by the overall bearish signals from the weekly indicators. The Dow Theory indicates a mildly bearish outlook on the weekly timeframe, while the monthly shows no trend. Overall, the strength of the current neutral stance is weak, driven primarily by conflicting signals across various indicators.

Are Indoco Remedies Ltd latest results good or bad?

Indoco Remedies Ltd's latest results are poor, showing a net loss of ₹29.79 crores for Q3 FY26, a 275.66% increase in losses from the previous quarter, alongside an 8.11% decline in revenue and a contraction in operating margin, indicating significant financial stress and operational challenges.

Indoco Remedies Ltd's latest results indicate a challenging financial situation. For Q3 FY26, the company reported a net loss of ₹29.79 crores, which represents a significant increase in losses of 275.66% compared to the previous quarter. Additionally, revenue declined by 8.11% quarter-on-quarter to ₹445.36 crores, reversing the positive growth seen in the prior quarter.<BR><BR>The operating margin also contracted to 7.25%, down from 9.12% in Q2 FY26, reflecting rising operational costs and inefficiencies. The interest burden has increased substantially, with interest expenses rising by 59.11% year-on-year, further straining profitability.<BR><BR>Overall, these results highlight ongoing structural challenges for Indoco Remedies, including elevated debt levels and deteriorating operational efficiency, which have led to a negative return on equity and significant financial stress. Given these factors, the latest results can be characterized as poor, indicating that the company is struggling to maintain stability and profitability.

Should I buy, sell or hold Indoco Remedies Ltd?

Why is Indoco Remedies Ltd falling/rising?

As of 31-Mar, Indoco Remedies Ltd's stock price is at Rs. 165.10, reflecting a 4.92% decrease and a new 52-week low. The company faces significant financial challenges, including a high Debt to EBITDA ratio and consistent negative results, contributing to its underperformance and declining stock price.

As of 31-Mar, Indoco Remedies Ltd's stock price is falling, currently at Rs. 165.10, which reflects a decrease of Rs. 8.55 or 4.92%. The stock has been on a downward trend, having lost 10.73% over the last three days and opening with a gap down of 3.83% today. Additionally, it has reached a new 52-week low of Rs. 163.7, indicating significant selling pressure.<BR><BR>The stock's performance has consistently underperformed against the benchmark, with a 1-year return of -29.29% compared to the BSE500's -7.06%. Over the past month, the stock has declined by 17.86%, while the Sensex fell only 10.33%. This trend of underperformance is further highlighted by the stock's returns over the last three years, where it has dropped by 49.60%, contrasting sharply with the Sensex's gain of 24.13%.<BR><BR>Financially, the company is facing challenges, including a high Debt to EBITDA ratio of 4.18 times, indicating a low ability to service its debt. The company has reported negative results for the last 13 consecutive quarters, and its operating profit has seen a drastic decline, growing at an annual rate of -175.27% over the past five years. This poor financial performance, coupled with a return on equity averaging only 9.06%, signifies low profitability and contributes to the stock's decline.<BR><BR>Overall, the combination of negative financial indicators, consistent underperformance against benchmarks, and recent selling pressure has led to the falling stock price of Indoco Remedies Ltd.

Which are the latest news on Indoco Remedies?